ClinicalTrials.gg
Not yet recruitingNCT07184060Updated Sep 19, 2025

Echocardiographic Assessment of Pulmonary Hypertension in Obstructive Sleep Apnea

An observational study in Obstructive Sleep Apnea (OSA) and Pulmonary Hypertension, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Assiut University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
55
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Sleep Apnea, Obstructive by Assiut University — 7 open to participants now, 7 under way, none of them phase 3. Sleep Apnea, Obstructive · Assiut University.

Planned enrollment
9th of 11
55 · median 80
Started
2025
the only one that year
Observational
11 of 13
6 open now
Registered
9th of 13
by date

Among the 13 studies in Sleep Apnea, Obstructive by Assiut University, this one is the 9th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2025, is one of 11 observational ones, and was the 9th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

7 of the 13 studies in Sleep Apnea, Obstructive by Assiut University are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Sleep Apnea, Obstructive by Assiut University, or all of them as a file.
02

Study summary

This study investigates the association between obstructive sleep apnea (OSA) and pulmonary hypertension (PH), focusing on the relationship between OSA severity and pulmonary arterial pressures in adult patients.

Read the detailed description

This prospective, observational, cross-sectional study will be conducted in the pulmonology and sleep medicine departments of Assiut University. Patients diagnosed with OSA through overnight polysomnography will be assessed for the presence and severity of PH using echocardiography. The study aims to determine whether OSA serves as an independent risk factor for PH and whether the severity of OSA, as measured by apnea-hypopnea index (AHI) and oxygen desaturation index (ODI), correlates with echocardiographic indicators of PH. Data will be analyzed using standardized statistical methods to establish links between OSA severity and hemodynamic changes.

03

Conditions studied

  • Obstructive Sleep Apnea (OSA)
  • Pulmonary Hypertension

Keywords

  • obstructive sleep apnea
  • pulmonary hypertension
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Eligible participants are 18-65 years old and diagnosed with OSA (AHI ≥ 5 events/hour) confirmed through full-night polysomnographic sleep study. Patients will be stratified into mild (AHI 5-14), moderate (AHI 15-29), and severe OSA (AHI ≥ 30). Exclusion criteria include patients with secondary PH (from cardiac causes, chronic thromboembolic disease, or pulmonary conditions), chronic vasodilator therapy, long-term oxygen therapy, advanced organ failure, neuromuscular or chest wall deformities, obesity hypoventilation syndrome, or malignancy. The expected sample size is 55 patients, ensuring enough statistical power to detect associations. Demographic, clinical, echocardiographic, radiological, and sleep study parameters will be collected for each patient.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults aged 18-65 years

Diagnosed with obstructive sleep apnea (OSA) by full-night polysomnography

Apnea-Hypopnea Index (AHI) ≥ 5 events/hour

Exclusion criteria

Exclusion Criteria:

Secondary pulmonary hypertension due to:Chronic pulmonary diseases, Left ventricular heart disease and Chronic thromboembolic disorders

Use of pulmonary vasodilator therapy

Long-term oxygen therapy (LTOT)

Respiratory neuromuscular weakness

Chest wall deformities

End-organ failure (cardiac, renal, hepatic)

Obesity hypoventilation syndrome

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
55 participants (estimated)
Patient registry
No

Groups and cohorts

  • adult patients with confirmed OSA

    Eligible participants are 18-65 years old and diagnosed with OSA (AHI ≥ 5 events/hour) confirmed through full-night polysomnographic sleep study. Patients will be stratified into mild (AHI 5-14), moderate (AHI 15-29), and severe OSA (AHI ≥ 30). Exclusion criteria include patients with secondary PH (from cardiac causes, chronic thromboembolic disease, or pulmonary conditions), chronic vasodilator therapy, long-term oxygen therapy, advanced organ failure, neuromuscular or chest wall deformities, obesity hypoventilation syndrome, or malignancy. The expected sample size is 55 patients, ensuring enough statistical power to detect associations. Demographic, clinical, echocardiographic, radiological, and sleep study parameters will be collected for each patient.

06

What researchers measure

Primary outcomes

  1. Mean Pulmonary Artery Pressure

    The primary objective is to assess the presence and degree of pulmonary hypertension (measured by echocardiography) in OSA patients.

    Time frame: baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Apr 2027, 18 months later.

Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 18 months is below that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2025
First posted
Sep 19, 2025
StartEst.
Oct 30, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Aug 30, 2027
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07184060
Lead sponsor
Assiut University
Responsible party
Ashraqat Tony Badawy (resident at the of Chest Diseases department, Assiut University) — Principal investigator
First posted
Sep 19, 2025
Start date
Oct 30, 2025 (estimated)
Primary completion
Apr 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Sep 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion